"Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)" by K. Baird

Article

Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)

Biology of Blood and Marrow Transplantation (2012)

K. Baird, National Institutes of Health
S. Booher, National Institutes of Health
L.E. Comis, National Institutes of Health
G.O. Joe, National Institutes of Health
S.M. Steinberg, National Institutes of Health
S.D. Spencer, National Institutes of Health
W.D. Figg, National Institutes of Health
N. Takebe, National Institutes of Health
S.Z. Pavletic, National Institutes of Health
E.W. Cowen, National Institutes of Health

Link

Disciplines

Publication Date

January 2, 2012

DOI

10.1016/j.bbmt.2011.12.018

Citation Information

K. Baird, S. Booher, L.E. Comis, G.O. Joe, et al.. "Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)" Biology of Blood and Marrow Transplantation Vol. 18 Iss. 2 (2012)
Available at: http://works.bepress.com/shawn-spencer/21/